IP Library › Granted Patent US 12,311,035
Granted Patent B2
US 12,311,035 · App. 17/280,606 · Granted May 27, 2025

Glymphatic delivery by manipulating plasma osmolarity

Inventors: Maiken Nedergaard (Rochester, NY); Benjamin Plog (Rochester, NY); Humberto Mestre Payne (Rochester, NY)
Assignee: University of Rochester
A61K49/0058A61K9/0085A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,311,035
App. No.
17/280,606
Granted
May 27, 2025
Kind
B2
Abstract

This invention relates to improving delivery of agents to the central nervous system.

Claims (26)

1. A method for improving delivery of a composition to a central nervous system interstitium, brain interstitium and/or a spinal cord interstitium of a subject comprising:

(1) enhancing glymphatic system influx by administering a hypertonic solution into plasma of the subject via intravenous, intraarterial, or intraperitoneal delivery, wherein the hypertonic solution comprises NaCl or Mannitol and is hypertonic with respect to the blood of the subject; followed by

(2) injecting the composition intracisternally or inrathecally to the central nervous system interstitium, brain interstitium and/or the spinal cord interstitium.

2. The method of claim 1 , wherein the step of enhancing glymphatic system influx further comprises pumping fluid through the central nervous system interstitium.

3. The method of claim 1 , wherein the hypertonic solution is administered via intravenous or intraperitoneal delivery.

4. The method of claim 1 , wherein the composition is injected intrathecally.

5. The method of claim 1 , wherein the composition is an imaging composition.

6. The method of claim 1 , wherein the composition is a therapeutic composition.

7. The method of claim 1 , wherein the composition comprises a small molecule, a virus, a large molecule, a peptide, an antibody, a nucleic acid, or a biologically active fragment thereof.

8. The method of claim 7 , wherein the therapeutic composition comprises an antibody.

9. The method of claim 8 , wherein the antibody is conjugated to a ligand that facilitates transport across the blood brain barrier (BBB).

10. The method of claim 9 , wherein the ligand specifically binds to a blood-brain barrier (BBB) receptor.

11. A method for treating a neurological disorder in a subject, comprising

(1) enhancing glymphatic system influx by administering a hypertonic solution into plasma of the subject via intravenous, intraarterial, or intraperitoneal delivery, wherein the hypertonic solution comprises NaCl or Mannitol and is hypertonic with respect to the blood of the subject; followed by

(2) injecting a therapeutic composition intracisternally or intrathecally to the central nervous system interstitium, brain interstitium and/or the spinal cord interstitium.

12. The method of claim 11 , wherein the step of enhancing glymphatic system influx further comprises pumping fluid through the central nervous system interstitium.

13. The method of claim 11 , wherein the hypertonic solution is administered via intravenous or intraperitoneal delivery.

14. The method of claim 11 , wherein the composition is injected intrathecally.

15. The method of claim 11 , wherein the therapeutic composition comprises a small molecule, a virus, a large molecule, a peptide, an antibody, a nucleic acid, or a biologically active fragment thereof.

16. The method of claim 15 wherein the therapeutic composition comprises an antibody.

17. The method of claim 16 , wherein the antibody is conjugated to a ligand that facilitates transport across the blood brain barrier.

18. The method of claim 17 , wherein the ligand specifically binds to a BBB receptor.

19. The method of claim 16 , wherein the antibody is an anti-Aβ antibody.

20. The method of claim 1 , wherein the subject is a mammal.

21. The method of claim 20 , wherein the mammal is a human or a non-human primate.

22. The method of claim 11 , wherein the neurological disorder is selected from the group consisting of a neuropathy, an amyloidosis, cancer, an ocular disease or disorder, a viral or microbial infection, inflammation, ischemia, neurodegenerative disease, seizure, behavioral disorder, and lysosomal storage disease.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 22, 2023
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065666/0296 →
Continuity (2)
Provisional Application 62741295 · Oct 4, 2018
Related Publication 20220031867A1 · Feb 3, 2022
References Cited (32)
US 9901650B2 · Nedergaard et al. · 2018 [cited by applicant]
US 20170105927A1 · Thorne · 2017 [cited by examiner]
US 20170145076A1 · Curran et al. · 2017 [cited by applicant]
US 20170202931A1 · DeKelver · 2017 [cited by examiner]
US 20180002722A1 · Asokan et al. · 2018 [cited by applicant]
US 20180134797A1 · Zhang et al. · 2018 [cited by applicant]
US 20180237496A1 · Chen et al. · 2018 [cited by applicant]
US 20180271796A1 · Zhang et al. · 2018 [cited by applicant]
CN 105228652A · 2016 [cited by applicant]
WO WO2014130777A1 · 2014 [cited by examiner]
WO WO2017210343A1 · 2017 [cited by examiner]
WO 2018015467A1 · 2018 [cited by applicant]
Robert G. L. Pullen, Michael Depasquale, and Helen F. Cserr; Bulk flow of cerebrospinal fluid into brain in response to acute hyperosmolality; Am. J. Physiol. 253 (Renal Fluid Electrolyte Physiol. 22): F538-F545, 1987 (… [cited by examiner]
Michelle E. Pizzo; Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery; (J Physiol 596.3 (2018) pp. 445-475;first published online Oct. 12, 2… [cited by examiner]
Bulk Flow of Cerebrospinal Fluid into Brain in Response to Acute Hyperosmolality (hereinafter the article is referred as Pullen), Intrathecal Antibody Distribution in the Rat Brain: Surface diffusion, perivascular trans… [cited by examiner]
Fowler, M. J. et al., “Intrathecal drug delivery in the era of nanomedicine”; Advanced Drug Delivery Reviews (2020); vol. 165-166; pp. 77-95. [cited by applicant]
Koffie, R. M. et al., “Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging”; PNAS (2011); vol. 108, No. 46; pp. 18837-18842. [cited by applicant]
Vulchanova, L. et al., “Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture”; Molecular Pain (2010); vol. 6; 9 pages. [cited by applicant]
Pullen, R. L. et al., “Bulk flow of cerebrospinal fluid into brain in response to acute hyperosmolality”; American Journal of Physiology (1987); vol. 253; pp. F538-F545. [cited by applicant]
Plog, B. A. et al., “The Glymphatic System in Central Nervous System Health and Disease: Past, Present and Future”; Annual Review of Pathology: Mechanisms of Disease (2018); vol. 13:1; pp. 379-394. [cited by applicant]
Russak, A. J et al., “Angiotensin II Increase Glymphatic Flow Through a Norepinephrine-Dependent Mechanisim”; Neurology Annual Meeting, AAN (2016); vol. 86:16, Suppl 1; p. P5.214. [cited by applicant]
Iliff, J. J., et al., “Cerebral Arterial Pulsation Drives Paravascular CFS-Interstitial Fluid Exchange in the Murine Brian”; The Journal of Neuroscience (2013); vol. 33:46, pp. 18190-18199. [cited by applicant]
Lundgaard, I. et al., “Beneficial Effects of Low Alcohol Exposure, but Adverse Effects of High Alcohol Intake on Glymphatic Function”; Scientific Reports (2018); vol. 8:1; 16 pgs. [cited by applicant]
Benveniste, H. et al., “Anesthesia with Dexmedetomidine and Low-Dose Isoflurane Increases Solute Transport via the Glymphatic Pathway in Rat Brain when Compared with High-Does Isoflurance”; Anesthesiology (2017); vol. 1… [cited by applicant]
Horiguchi, N. et al., “Liver Regeneration is Suppressed in Alcoholic Cirrhosis Correlation with Decreased STAT3 Activation”; Alcohol (2007); vol. 41; pp. 271-280. [cited by applicant]
Starkel, P. et al., “Deficient Stat3 DNA-Binding is Associated with high Pias3 Expression and a Positive Anti-Apoptotic Balance in Human End-Stage Alcoholic and Hepatits C Cirrhosis”; Journal of Hepatology (2005); vol. … [cited by applicant]
Koffie, R. M. et al., “Nanoparticles Enhance Brain Delivery of Blood-Brain Barrier-Impermeable Probes for in vivo Optical and Magnetic Resonace Imaging”; PNAS (2011); vol. 108:46; pp. 18837-18842. [cited by applicant]
Thakker, D. R. et al., “Intracerebroventricular Amyloid-Beta Antibodies Reduce Cerebral Amyloid Angiopathy and Associates Micro-Hemorrhages in aged Tg2576 Mice”; PNAS (2009); vol. 106:11; pp. 4501-4506. [cited by applicant]
Sun, B. et al., “Lymphatic Drainage System of the Brain: A Novel Targe for Intervention of Neurological Diseases”; Progress in Neurobiology (2018); vol. 163: Sp., pp. 118-143. [cited by applicant]
Vulchanova, L. et al., “Differential Adeno-Associated Virus Mediated Gene Transfer to Sensory Neurons Following Intrathecal Delivery by Direct Lumbar Puncture”; Molecular Pain (2010); vol. 6:31, 9 pgs. [cited by applicant]
Sonoda, “BBB-penetrating technology” Farumashia, vol. 52, No. 11, 2016, pp. 1051-1053. [cited by applicant]
Wadghiri et al., “Detection of Alzheimer's Amyloid in Transgenic Mice Using Magnetic Resonance Microimaging”, Magnetic Resonance in Medicine, vol. 50, pp. 293-302. [cited by applicant]